Skip to main content
Premium Trial:

Request an Annual Quote

Hans Peter Fatscher, David Barker, John Stark, Heino von Prondzynski, Bruce Carter

Qiagen said this week that it has promoted Hans Peter Fatscher to the position of vice president of sales, life sciences. He will be responsible for the life sciences sales organization in North America. He most recently served as director of global customer satisfaction for the company.

Former Illumina chief scientific officer David Barker has joined NextBio’s board of directors, NextBio said last week.
Before working at Illumina, Barker was chief science advisor at Amersham Biosciences, and served as vice president of research and business development at Molecular Dynamics.
Baker also worked in interdisciplinary neurobiological research at Harvard Medical School.

ClinXus, a western-Michigan non-profit promoting the region as a locale for pharmaceutical and medical device companies, this week named John Stark its executive director.
Stark formerly was a sales manager at Affymetrix. He is a native of the region and previously worked as a project manager for the Industrial Experimental and Manufacturing Co., and as an engineer for Motorola’s life sciences segment.

Epigenomics has proposed electing former Roche Diagnostics CEO Heino von Prondzynski to its supervisory board.
The vote would take place during Epigenomics’ next annual general meeting of shareholders. The company made the decision during a March 1 meeting of its supervisory board.
If elected, von Prondzynski would replace Zymogenetics CEO Bruce Carter.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.